Cite
Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer.
MLA
Jiang, Xianhan, et al. “Elevated Levels of Mitochondrion-Associated Autophagy Inhibitor LRPPRC Are Associated with Poor Prognosis in Patients with Prostate Cancer.” Cancer (0008543X), vol. 120, no. 8, Apr. 2014, pp. 1228–36. EBSCOhost, https://doi.org/10.1002/cncr.28551.
APA
Jiang, X., Li, X., Huang, H., Jiang, F., Lin, Z., He, H., Chen, Y., Yue, F., Zou, J., He, Y., You, P., Wang, W., Yang, W., Zhao, H., Lai, Y., Wang, F., Zhong, W., & Liu, L. (2014). Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer. Cancer (0008543X), 120(8), 1228–1236. https://doi.org/10.1002/cncr.28551
Chicago
Jiang, Xianhan, Xun Li, Hai Huang, Funeng Jiang, Zhuoyuan Lin, Huichan He, Yanru Chen, et al. 2014. “Elevated Levels of Mitochondrion-Associated Autophagy Inhibitor LRPPRC Are Associated with Poor Prognosis in Patients with Prostate Cancer.” Cancer (0008543X) 120 (8): 1228–36. doi:10.1002/cncr.28551.